Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen

Oncogene

Volumn 30, Issue 24, 2011, Pages 2789-2797

  Tauchi, T ^a   Okabe, S ^a   Ashihara, E ^b   Kimura, S ^c   Maekawa, T ^d   Ohyashiki, K ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

BCR ABL; HSP90; nilotinib; T315I; tyrosine kinase inhibitor

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; BCR ABL PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; NILOTINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG RESISTANCE; ESCHERICHIA COLI; GROWTH INHIBITION; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL LINE; MONONUCLEAR CELL; MOUSE; MUTAGENESIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; CELL LINE, TUMOR; FUSION PROTEINS, BCR-ABL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MUTAGENESIS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RESORCINOLS;

MUS;

EID: 79958829892     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.3     Document Type: Article

References (23)

1. Azam M, Latek R, Daley GQ. (2003). Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843. (Pubitemid 36378885)
2. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotech 25: 1035-1044. (Pubitemid 47517638)
3. Branford S, Melo JV, Hughes PT. (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114: 5426-5435.
4. Brough PA, Aherne W, Barril X, Borgogononi J, Boxall K, Cansfield JE et al. (2008). 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196-218.
5. Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y et al. (2008). Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32: 980-983.
6. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M et al. (2008). NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860. (Pubitemid 351556284)
7. Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z et al. (2009). The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114: 4361-4368.
8. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. (2002). BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100: 3041-3044.
9. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S et al. (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112: 53-55.
10. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y et al. (2001). In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999-2007. (Pubitemid 32239079)
11. Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J et al. (2009). Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113: 6322-6329.
12. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brian S, Wassmann B et al. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551. (Pubitemid 43882350)
13. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki P, Jootar S et al. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109: 5143-5150. (Pubitemid 46890528)
14. Matsuyama W, Wang L, Farrar WL, Faure M, Yoshimura T. (2004). Activation of discoidin domain receptor 1 isoform b with collagen up-regulates chemokine production in human macrophages: role of p38 mitogen-activated protein kinase and NF-kappa B. J Immunol 172: 2332-2340. (Pubitemid 38182381)
15. Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, Sashida G et al. (2007). Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene 26: 4179-4188. (Pubitemid 46920165)
16. O'Hare T, Eide CA, Deininger MWN. (2007). Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249. (Pubitemid 47523141)
17. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA et al. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110: 2309-2315. (Pubitemid 47523149)
18. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. (2007). Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109: 5011-5015. (Pubitemid 46827801)
19. Rix U, Hantschel O, Dumberger G, Remsing Rix LL, Planyavsky M, Feenbach NV et al. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063. (Pubitemid 350248462)
20. Shah NP, Tran C, Lee FY, Chen P, Norris D, Saywers CL. (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401. (Pubitemid 38938156)
21. Stuhmer T, Zollinger A, Siegmund D, Chatterjee M, Grella E, Knop S et al. (2008). Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22: 1604-1612.
22. Tauchi T, Boswell HS, Leibowitz D, Broxneyer HE. (1994). Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179: 167-175. (Pubitemid 24012981)
23. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141. (Pubitemid 40248339)